Author

Elaina Haeuber

Observed name: ELAINA HAEUBER

Institution: Premier Research Group

Observed institutions: University of Maryland, Baltimore, Hackensack University Medical Center, University of Washington, Actinium Pharmaceuticals (United States), Baltimore VA Medical Center, Premier Research Group

OpenAlex ID: A5000521187

Microprocessor-based ambulatory activity monitoring in stroke patients

2002 · RICHARD F. MACKO, ELAINA HAEUBER, et al. · Medicine & Science in Sports & Exercise · 186

Accelerometer monitoring of home- and community-based ambulatory activity after stroke11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.

2004 · Elaina Haeuber, Marianne Shaughnessy, et al. · Archives of Physical Medicine and Rehabilitation · 182

Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

2024 · Boglarka Gyurkocza, Rajneesh Nath, et al. · Journal of Clinical Oncology · 20

S248: Sierra Trial Results With a Targeted Radiotherapy, Iomab-b, a Myeloablative Conditioning With Reduced Intensity Tolerability Yields High Cr, Long Term Survival in Hsct Ineligible Active R/r Aml

2023 · Boglarka Gyurkocza, Stuart Seropian, et al. · HemaSphere · 7

131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

2023 · Hannah Choe, Ben K. Tomlinson, et al. · Blood · 2

High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

2023 · Mark R. Litzow, George Chen, et al. · Blood · 2

131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

2023 · Stuart Seropian, James M. Foran, et al. · Blood · 1

Escalating site burden and cost: What’s driving the surge in oncology investigator grants over the past decade.

2026 · Ashley Herrick, Meera Belur, et al. · Journal of Clinical Oncology

Quality-driven medical oversight in global oncology trials: Standardizing immune-related AE management to enhance patient safety.

2026 · Radhika Shah, Salini Sathya Naidu, et al. · Journal of Clinical Oncology

Early-phase operational readiness gaps in oncology cell and gene therapy trials and implications for scalable trial infrastructure.

2026 · Meera Belur, Ashley Herrick, et al. · Journal of Clinical Oncology

Abstract 5517: Standardizing global patient safety and site compliance in oncology trials using a configurable, technology-driven oversight model.

2026 · Ashley Herrick, Dmitri Berman, et al. · Cancer Research

AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies

2023 · Rajneesh Nath, Stuart Seropian, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies

2023 · Rajneesh Nath, Stuart Seropian, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 13

Citation count: 400

H-index: 4

I10-index: 3